1. Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study 
Christopher R. Chapple, Salman H. Al-Shukri, Bernard Gattegno, Simon Holmes, José M. Martínez-Sagarra, Roberto M. Scarpa, Oncko B. van Vierssen Trip, Viktor Vik, Ingrid van der Putten-Slob 
European Urology Supplements 
Volume 4, Issue 2, Pages (February 2005)
DOI: /j.eursup
Copyright © 2004 Elsevier B.V. Terms and Conditions

2. Fig. 1
Flow diagram of the number of patients enrolled, randomised and completing the study per treatment group.
European Urology Supplements 2005 4, 33-44DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

3. Fig. 2 Mean change in total I-PSS from baseline to endpoint (ITT).
European Urology Supplements 2005 4, 33-44DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

4. Fig. 3 Effect of treatment on mean total I-PSS over time (ITT).
European Urology Supplements 2005 4, 33-44DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

5. Fig. 4
Percentage of patients with all dizziness and abnormal ejaculation MedDRA coded terms combined (SAF). Abnormal ejaculation: p= for tamsulosin MR 0.4mg vs. placebo, p= for tamsulosin OCAS 0.8mg vs. placebo and p= for tamsulosin OCAS 0.8mg vs. tamsulosin OCAS 0.4mg.
European Urology Supplements 2005 4, 33-44DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

6. Fig. 5
Mean change in supine SBP and DBP from baseline to 12 weeks of treatment (SAF).
European Urology Supplements 2005 4, 33-44DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions